# Final Reporting for JPIAMR funded projects

The coordinator needs to collect information from each of the partners for the following aspects of the project reporting and compile them in the final report to be submitted.

## 1- Project Details

### Project title

(free text)

### Project acronym

(free text)

### Dates

### Project start date: DD/MM/YYYY

### Project end date: DD/MM/YYYY

### Date of consortium agreement: DD/MM/YYYY

### Date of report: DD/MM/YYYY

## 2 - Details of the project coordinator and partners

### Please provide the following information of the partners in the consortium

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Firstname Lastname** | **Gender**  (F / M / Other) | **Country** | **E-mail** | **Amount Awarded** (in Euros) |
| Coordinator |  |  |  |  |  |
| Partner1 |  |  |  |  |  |
| Partner2 |  |  |  |  |  |
| …. |  |  |  |  |  |

Additional details of the project partners

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Partner Number** | **Organisation** | **Type of organisation**  (Use one of the following options:  University, Research institute, SME/ Industry, Public Health, Hospitals/ Health care, Other) | **Nature of organisation** (Use one of the following options: Public, Private, Non-profit) | **Researcher Identification**  (ORCID ID or Researcher ID) |
| Coordinator |  |  |  |  |
| Partner1 |  |  |  |  |
| Partner 2 |  |  |  |  |
| …. |  |  |  |  |

## 3 - JPIAMR pillars and scientific area

Please allocate the relevance of each JPIAMR priority pillar with respect to the project (total 100%)

### Therapeutics -

### Intervention -

### Surveillance -

### Transmission -

### Environment -

### Diagnostics -

## 4 - Which of the following scientific areas and keywords are relevant to the project?

Air

Agriculture

Alternatives to antibiotics

Animal borne transmission

Aquaculture

Clinical trial

Combination therapy

Community settings

Companion animals (pets)

Detection of resistance

Drinking water

Economy

Epidemiology

Feed

Food

Food borne transmission

Health care settings

Hospitals

Humans

Improve existing antibiotics

Industry

Innovations

Intervention measures

Lead optimization or drug discovery

Livestock

Low- and middle-income countries (LMIC)

Misuse of antibiotics

Nanoparticles

Neglected and disused antibiotics

Narrow-spectrum antibiotics

New interventions

New prevention measures

New strategy

New target

New therapy

New tools/assays

Next generation sequencing

One Health

Phage

PK/PD modelling

Political and social awareness

Pre-clinical

Public Health

Rapid detection

Rivers, lakes, streams

Seas and oceans

Sewage and waste water treatment

Social science

Soil

Stewardship

Strain typing

Vaccine

Veterinary

Water borne transmission

WHO priority pathogens

Wildlife

Other

### If Other, please specify

## 5 – Bacterial pathogen/s studied in the project and respective category as identified in the WHO [Global priority list](http://www.who.int/medicines/areas/rational_use/PPLreport_2017_09_19.pdf?ua=1) of antibiotic-resistant bacteria.

|  |  |  |
| --- | --- | --- |
| Name of the pathogen (s) | Resistance identified | Prioritisation of the pathogen as per WHO Global priority list  (Critical, High or Medium priority) |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

## 6 - Ethical considerations

### Please confirm you had all the needed ethical permits to perform the project work.

Confirm

Do not confirm

If no ethical permit(s) were obtained, please specify the reason.  
(For eg. Not relevant to the project, under process etc.)

Please attach the ethical permit(s).  
(If multiple files, combine into one PDF or attach a compressed folder)

Is there a gender dimension to the topic or execution of the project?  
(e.g gender (im)balance of the samples used, different risk or impact on a specific gender)

Yes

No

* If Yes
* Please describe the gender dimension of the project. (Max 1500 characters.)  
  (free text)

## 7 - Tasks and deliverables

Please describe briefly the main project tasks/deliverables according to the original proposal.

* Task 1
* Task 2
* Task 3
* …….
* Task 10

### Please provide the following details of the progress of the tasks/deliverables mentioned above

Do not provide information supplied in the mid-term report in order to avoid duplication.

When indicating the partners, please use partner abbreviations (P1, P2) to refer to the project partner table earlier in the document.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Tasks | Partners involved (P1, P2) | Date planned  (DD-MM-YYYY) | Date of delivery (DD-MM-YYYY) | Task completed? (Y / N) | Main difficulties\* (Use from options mentioned below) |
| Task 1 |  |  |  |  |  |
| Task 2 |  |  |  |  |  |
| Task 3 |  |  |  |  |  |
| Task 4 |  |  |  |  |  |
| Task 5 |  |  |  |  |  |
| Task 6 |  |  |  |  |  |
| Task 7 |  |  |  |  |  |
| Task 8 |  |  |  |  |  |
| Task 9 |  |  |  |  |  |
| Task 10 |  |  |  |  |  |

\*Main difficulties  
(Please use the most suitable of these options when filling out the above table)

None

Experimental, methodological or technical issues

Staffing matters (e.g. skills shortages, recruitment delays, unexpected extended leave or departure of staff)

Access to archives, data or participants

Other resourcing issues (e.g. difficulty/delay in securing key equipment)

Unrealistic initial objectives

Higher than anticipated risk levels

Changing landscape of research program

Regulatory issues

Difficulties with collaborative partners

Other

### Please discuss any other difficulties you encountered

(free text)

## 8 - Work summary

### Briefly describe the work performed during the entire period (including the mid-term) along with the aims and the main objectives listed. Highlight any significant findings or conclusions from the project. (max 3000 characters)

(free text)

## 9 - Consortium meetings

### Please list the consortium meetings

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Topic/Type of meeting | Date (DD-MM-YYYY) | Partners present  (P1, P2, etc.) | Other invited participants present (Name, Country, Organisation) |
| 1 |  |  |  |  |
| 2 |  |  |  |  |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
| 5 |  |  |  |  |
| 6 |  |  |  |  |
| 7 |  |  |  |  |
| 8 |  |  |  |  |
| 9 |  |  |  |  |
| 10 |  |  |  |  |

## 10 - Research output - Published work

### Which of the following output types has the project so far resulted in

Scientific article (published)

☐ Book

Thesis

Conference participation

Manual/Guide

Monograph

Policy briefing report

Technical Report

Technical Standard

Consultancy Report

White paper

Other

### If Other, please specify

* If “Scientific article (published)” selected:

### Please fill in the flowing information about your scientific articles(s)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| General info | | | Published open access? | |
| Type \* | DOI | PMID | Yes | No |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

\* Options: Original work, Review, Proceedings

* If “Book” selected:

### Please fill in the flowing information about your contribution to books

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Type of thesis | | | | ISBN-number (if available) |
| Main author | Author of chapter | Editor | Other |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

* If “Thesis” selected:

### Please fill in the flowing information about any thesis resulting from this project

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Type of participation | | | | ISBN-number |
| Bachelor | Master | Doctoral | Other |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

* If “Conference participation” selected:

### Please fill in the flowing information about conference participation related to this project

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Type of participation | | | | Scope of conference | |
| Oral | Poster | Organiser | Other | National | International |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

## 11 - Research output - Medical products, Interventions

### Has the project been involved in the development of medical products or interventions?

Yes

No

* If Yes:

### Please give the following information of the medical products and interventions

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Type of research output** (Use one of the following options: Medical Product, Intervention, Therapeutic, Diagnostic) | **Current stage** (Use one of the following options:  Preclinical development, Clinical assessment, Market authorisation) | **Partners involved** (P1, P2) | **URLs** | **Related clinical trial?** (Y / N) | **Clinical trial number** |
| 1 |  |  |  |  |  |  |
| 2 |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |
| 4 |  |  |  |  |  |  |
| 5 |  |  |  |  |  |  |
| 6 |  |  |  |  |  |  |
| 7 |  |  |  |  |  |  |
| 8 |  |  |  |  |  |  |
| 9 |  |  |  |  |  |  |
| 10 |  |  |  |  |  |  |

Please provide a short description of the product(s) or intervention(s). Indicate any notable impact(s) arising from the development process. (max 3000 characters)  
(free text)

## 12 - Research resources generated

### Please indicate how many of the following have been created/ generated or newly characterised in the project. Please add a brief description and/or URL

|  |  |  |
| --- | --- | --- |
|  | **Indicate Numbers** | **Brief explanation or URLs** |
| Cell lines |  |  |
| Microbial strains |  |  |
| Collection of Samples |  |  |
| New lead molecule |  |  |
| Technology assay or reagent |  |  |
| Database or collection of data |  |  |
| Data analysis technique |  |  |
| Computer model or algorithm |  |  |
| Course (e.g. MOOC) |  |  |
| Business model |  |  |
| Web tool or application |  |  |
| Software |  |  |
| E-business platform |  |  |
| Grid application |  |  |
| Physical model or kit |  |  |
| Devices |  |  |
| Other |  |  |

### Please discuss any other research resources generated (max 1000 characters)

free text)

## 13 - Intellectual property and licensing

### How many of the following protections have been pursued with regards to the project?

|  |  |  |
| --- | --- | --- |
|  | URL | Please provide a brief explanation  (free text) |
| Copyright (e.g. software) |  |  |
| Trademark |  |  |
| Patent |  |  |

## 14 – Start-up companies

### Has any company arisen as a result of the research carried out in this project?

Yes

No

* If Yes:

### Please provide a brief explanation

(free text)

### Please provide links

* URL

## 15 - Personnel recruited through the project

### Have any personnel been financed through the project supported by JPIAMR?

(e.g. bachelor or master student, doctoral, postdoctoral, engineer or equivalent, technician, individual contractor etc.)

Yes

No

* If Yes, please indicate number for each option

|  |  |
| --- | --- |
| Gender | Number recruited |
| Female |  |
| Male |  |
| Other |  |

### Type of position (indicate number for each option)

|  |  |
| --- | --- |
| Position | Number recruited |
| Bachelor |  |
| Master |  |
| Doctoral |  |
| Post-doctoral |  |
| Engineer or equivalent |  |
| Technician |  |
| Individual contractor |  |
| Other |  |

* If other

Please specify the other types of employment  
free text)

## 16 - Training and Mobility

Summarise below if any of the personnel supported by the JPIAMR grant visited another lab/facility to gain training or knowledge transfer through mobility

### Has anyone financed by the JPIAMR grant gained training through mobility or exchange opportunities?

Yes

No

If Yes, please indicate number for each option

|  |  |
| --- | --- |
| Gender | Number recruited |
| Female |  |
| Male |  |
| Other |  |

### Type of position (indicate number for each option)

|  |  |  |
| --- | --- | --- |
| **Position** | **Type of position** (indicate number for each option) | **Nature of mobility**  (Select from one of the following options:  Exchange of personnel, Training of personnel,  Access to infrastructure/facility, Exchange on research approaches/methods) |
| Doctoral |  |  |
| Post-doctoral |  |  |
| Technician |  |  |
| Other |  |  |

* If other

### Please specify the other types of positions (free text)

## 17 - External collaborations

### Please provide the following information about collaborations of the JPIAMR partners with other countries outside the consortium.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Country of the JPIAMR partner** | **Country of the External collaborator** | **Type of organization**  (Use one of the following options:  University, Research institute, SME/ Industry, Public Health, Hospitals/ Health care, Other)) | **Nature of collaboration**  (Use the most suitable of the following options:  Exchange of personnel (e.g. training for students or employees), Joint publications (e.g. articles, communication and dissemination), Joint conferences, events or networks, In-depth exchanges on research materials approaches, methods or results, Use of infrastructure, R&D service (e.g. tech development, GMP production etc.), Other) |
| 1 |  |  |  |  |
| 2 |  |  |  |  |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
| 5 |  |  |  |  |
| 6 |  |  |  |  |
| 7 |  |  |  |  |
| 8 |  |  |  |  |
| 9 |  |  |  |  |
| 10 |  |  |  |  |

### Please discuss any other forms of collaboration

(free text)

## 18 - Impact on Policy, Practice, Patients and Public

### Which of the following impacts has the project resulted in thus far

Improvement in survival, morbidity or quality of life

Improved public services (e.g. accessibility, efficiency and effectiveness)

Improved regulatory environment

Economic impacts

Improved educational and skill level of workforce

Changed public attitudes on social issues

Effective solutions to societal problems

Improved environmental sustainability

Other

If Other, please specify

(free text)

### In which ways has the project gained this impact?

Training of practitioners (medical doctors, veterinarians, farmers, etc)

Training of patients

Training of researchers

Citation in clinical guidelines or reviews

Citation in other policy documents

Citation in systematic reviews

Participation in national consultation or advisory committee

Other

If Other, please specify

(free text)

### What would you consider the reach of the impact?

Local / municipal / regional

National

International

### Briefly describe the reach and significance of the impact generated by the project. (max 1000 characters)

(free text)

### Please provide any available reference details to relevant documents.

|  |  |  |  |
| --- | --- | --- | --- |
| **URL** | **DOI** | **ISBN** | **Other** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

## 19 - Outreach activities

### Please provide a popular science summary of the project. (max 1500 characters)

The text might be used for communications/dissemination of JPIAMR funded projects.

This is not a scientific abstract and should be understandable by the general audience.

(free text)

### Please provide at least one image or video related to the project that can be used for communication purposes.

(Attach video file or paste image here)

### Which of the following audiences has the project been communicated to?

Patient groups

Professional Practitioners

Media (newspaper, television etc.)

Social media

General public

Policymakers

Students (pre-graduate)

Academic audiences

Other

None/ not relevant

* If other

Please describe the other types of audiences you have communicated the project to  
 (free text)

### What would you consider the reach of the activities?

Local / municipal / regional

National

International

### Do any of the partners of the JPIAMR supported project have websites or blogs mentioning the project?

Yes

No

* If Yes:

### Please provide URLs

(free text)

## 20 - Further funding

### Has this collaboration received additional funding for complementary or follow-up activities?

* Yes
* No
* If Yes:

### Please provide the following information about any further funding

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Recipient’s Name** | **Name of the organisation that provided the funding** | **Year of funding** | **Type of funding**  (Use one of the following options:  Research grant, Fellowship, Capital/infrastructure, Travel, Other) |
| 1 |  |  |  |  |
| 2 |  |  |  |  |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
| 5 |  |  |  |  |
| 6 |  |  |  |  |
| 7 |  |  |  |  |
| 8 |  |  |  |  |
| 9 |  |  |  |  |
| 10 |  |  |  |  |

### Please specify other types of funding

(free text)

## 21 - Comments and Feedback

### Please provide any comments and feedback you might have to JPIAMR.

(free text)